These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16098254)

  • 1. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.
    Zhang W; Stoehlmacher J; Park DJ; Yang D; Borchard E; Gil J; Tsao-Wei DD; Yun J; Gordon M; Press OA; Rhodes K; Groshen S; Lenz HJ
    Clin Colorectal Cancer; 2005 Jul; 5(2):124-31. PubMed ID: 16098254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab.
    Zhang W; Gordon M; Press OA; Rhodes K; Vallböhmer D; Yang DY; Park D; Fazzone W; Schultheis A; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
    Pharmacogenet Genomics; 2006 Jul; 16(7):475-83. PubMed ID: 16788380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
    Graziano F; Ruzzo A; Loupakis F; Canestrari E; Santini D; Catalano V; Bisonni R; Torresi U; Floriani I; Schiavon G; Andreoni F; Maltese P; Rulli E; Humar B; Falcone A; Giustini L; Tonini G; Fontana A; Masi G; Magnani M
    J Clin Oncol; 2008 Mar; 26(9):1427-34. PubMed ID: 18349392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation.
    Zhang W; Park DJ; Lu B; Yang DY; Gordon M; Groshen S; Yun J; Press OA; Vallböhmer D; Rhodes K; Lenz HJ
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):600-5. PubMed ID: 15701846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
    Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
    Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy.
    Lai CY; Sung FC; Hsieh LL; Tang R; Chiou HY; Wu FY; Yeh CC
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S599-606. PubMed ID: 23800895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.
    Han SW; Oh DY; Im SA; Park SR; Lee KW; Song HS; Lee NS; Lee KH; Choi IS; Lee MH; Kim MA; Kim WH; Bang YJ; Kim TY
    Cancer Sci; 2010 Mar; 101(3):793-9. PubMed ID: 20047592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.
    Schultheis AM; Lurje G; Rhodes KE; Zhang W; Yang D; Garcia AA; Morgan R; Gandara D; Scudder S; Oza A; Hirte H; Fleming G; Roman L; Lenz HJ
    Clin Cancer Res; 2008 Nov; 14(22):7554-63. PubMed ID: 19010874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer.
    Lv H; Li Q; Qiu W; Xiang J; Wei H; Liang H; Sui A; Liang J
    Pathol Oncol Res; 2012 Oct; 18(4):1009-14. PubMed ID: 22549274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer.
    Stoehlmacher J; Park DJ; Zhang W; Groshen S; Tsao-Wei DD; Yu MC; Lenz HJ
    J Natl Cancer Inst; 2002 Jun; 94(12):936-42. PubMed ID: 12072547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating
    Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
    World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
    Bonin S; Donada M; Bussolati G; Nardon E; Annaratone L; Pichler M; Chiaravalli AM; Capella C; Hoefler G; Stanta G
    Tumour Biol; 2016 Jun; 37(6):7295-303. PubMed ID: 26666825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.
    Stoehlmacher J; Ghaderi V; Iobal S; Groshen S; Tsao-Wei D; Park D; Lenz HJ
    Anticancer Res; 2001; 21(4B):3075-9. PubMed ID: 11712813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
    Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
    Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer.
    Lv H; Li Q; Qiu W; Xiang J; Wei H; Liang H; Sui A; Liang J
    Cancer Invest; 2013 Jan; 31(1):24-8. PubMed ID: 23327191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
    Zhang X; Shimodaira H; Soeda H; Komine K; Takahashi H; Ouchi K; Inoue M; Takahashi M; Takahashi S; Ishioka C
    Int J Clin Oncol; 2016 Dec; 21(6):1091-1101. PubMed ID: 27435270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy.
    Huang CW; Ma CJ; Su WC; Chen YT; Tsai HL; Yeh YS; Chang TK; Hsu WH; Yu FJ; Wang JY
    Oncol Res; 2021 Sep; 28(7):701-714. PubMed ID: 32859280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.